Mr. Stamoran leads Catalent’s strategic planning and market intelligence efforts, as well as supporting its global M&A and technology acquisition activities. He also serves at Catalent’s investor relations officer.
Cornell has spent nearly 25 years engaged with the health care industry, including 20 years’ in advanced drug delivery. Cornell has been fortunate to experience the realities of patient adherence and outcomes enhancement from almost every stakeholder perspective. Cornell has gained frontline experience on the realities of patient adherence and outcomes enhancement, from direct engagement with retail and hospital pharmacists; medical professionals; specialty pharmacies and clinics; PBMs; and payors. Cornell has directly participated in the development of drug design-enabled adherence and outcomes enhancement strategies for more than 150 branded drugs over the last 10 years.
During his 20 year tenure at Catalent, Mr. Stamoran has held many roles across a variety of disciplines, including financial and tax accounting; SEC reporting and financial planning; strategic business and technology planning; sales/business development; market intelligence; corporate development; marketing and branding; innovation; and public and investor relations. He holds several professional certifications, and is a graduate of the University of Michigan.